Omega-3 fatty acids and atorvastatin suppress ventricular fibrillation inducibility in hypertriglyceridemic rat hearts: Implication of intercellular coupling protein, connexin-43

Journal of Physiology and Pharmacology

Volumn 61, Issue 6, 2010, Pages 717-723

  Bacova, B ^a   Radosinska, J ^b   Knezl, V ^c   Kolenova, L ^b   Weismann, P ^b   Navarova, J ^c   Barancik, M ^a   Mitasikova, M ^a   Tribulova, N ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL PHARMACOLOGY AND TOXICOLOGY   (Slovakia)

Author keywords

Atorvastatin; Cholesterol; Hypertriglyceridemic rat; Myocardial connexin 43; Omega 3 fatty acids; Remodelling; Ventricular fibrillation

Indexed keywords

ATORVASTATIN; CONNEXIN 43; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR RESPONSE; CELL JUNCTION; CONTROLLED STUDY; DRUG EFFICACY; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE FIBRILLATION; HYPERTRIGLYCERIDEMIA; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; ARRHYTHMIAS, CARDIAC; BLOOD PRESSURE; CONNEXIN 43; FATTY ACIDS, OMEGA-3; HEART RATE; HEART VENTRICLES; HEPTANOIC ACIDS; HYPERTRIGLYCERIDEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PYRROLES; RATS; RATS, WISTAR; TRIGLYCERIDES; UP-REGULATION; VENTRICULAR FIBRILLATION;

EID: 79251485992     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Goldberg IJ. Hypertriglyceridenia: impact and treatment. Endocrinol Metab Clin North Am 2009; 38: 137-149.
2. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176: 1113-1120.
3. Hegele RA, Pollex RL. Hypertriglyceridemia: phenomics and genomics. Mol Cell Biochem 2009; 326: 35-43.
4. Zicha J, Pechanova O, Cacanyiova S, et al. Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome? Physiol Res 2006; 55(Suppl 1): 49-63
5. Tribulova N, Fialova M, Dlugosova K, et al. Myocardial gap junction remodelling in hypertriglyceridemic rat heart is associated with increased vulnerability to ventricular fibrillation. Cardiology 2006; 15: 32.
6. Peters NS, Wit AL. Myocardial architecture and ventricular arrhythmogenesis. Circulation 1998; 97: 1746-1754.
7. Severs NJ, Dupont E, Coppen SR, et al. Remodelling of gap junctions and connexin expression in heart disease. Biochim Biophys Acta 2004; 1662: 138-148.
8. Saffitz JE, Schuessler RB, Yamada KA. Mechanisms of remodeling of gap junction distributions and the development of anatomic substrates of arrhythmias. Cardiovasc Res 1999; 42: 309-317.
9. Saffitz JE, Hames KY, Kanno S. Remodeling of gap junctions in ischemic and nonischemic forms of heart disease. J Membr Biol 2007; 218: 65-71.
10. Tribulova N, Knezl V, Okruhlicova L, Slezak J. Myocardial gap junctions: targets for novel approaches in the prevention of life-threatening cardiac arrhythmias. Physiol Res 2008; 57: 1-13.
11. Dhein S. Gap junctional channels in cardiovascular system: pharmacological and physiological modulation. Trends Pharmacol Sci 1998; 19: 229-241.
12. Salameh A, Dhein S. Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochim Biophys Acta 2005; 1719: 36-58.
13. Lin H, Mitasikova M, Dlugosova K, et al. Thyroid hormones suppress epsilon-PKC signalling, down-regulate connexin- 43 and increase lethal arrhythmia susceptibility in non- diabetic and diabetic rat hearts. J Physiol Pharmacol 2008; 59: 271-285.
14. Peters NS, Coromilas J, Severs NJ, Vit AL. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997; 95: 988-996.
15. DeGroot JR, Coronel R. Acute ischemia-induced gap junctional uncoupling and arrhythmogenesis. Cardiovasc Res 2004; 62: 323-334.
16. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation 2000; 101: 547-552.
17. +-induced ventricular fibrillation. Physiol Res 2001; 50: 247-259.
18. Tribulova N, Okruhlicova L, Novakova S, et al. Hypertension-related intermyocyte junction remodelling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. Exp Physiol 2002; 87: 195-205.
19. Tribulova N, Knezl V, Shainberg A, Seki S, Soukup T. Thyroid hormones and cardiac arrhythmias. Vascul Pharmacol 2010; 52: 102-112.
20. Anderson KP. Lipid-lowering therapy for prevention of ventricular tachyarrhythmias. JACC 2003; 42: 88-92.
21. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AF, AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. JACC 2003; 42: 81-87.
22. Sacks FM, Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med 2002; 113: 13-24.
23. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003; 107: 2646-2652.
24. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E in 11,324 patients with myocardial infarction: results of the GISSI- Prevenzione Trial. Lancet 1999; 354: 447-455.
25. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 1999; 99: 2452-2457.
26. Mitasikova M, Smidova S, Macsaliova A, et al. Aged male and female spontaneously hypertensive rats benefit from n-3 polyunsaturated fatty acids supplementation. Physiol Res 2008; 57(Suppl 2): S39-S48.
27. London B, Albert C, Anderson ME, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007; 116: 320-335.
28. Charnock JS, Abeywardena MY, Poletti VM, McLennan PL. Differences in fatty acid composition of various tissues of the marmoset monkey (Callithrix jacchus) after lipid supplemented diets. Comp Biochem Physiol 1992; 101: 387-393.
29. Pound EM, Kang JX, Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 2001; 42: 346-351.
30. Nair SS, Leitch JW, Falconer J, Garg ML. Prevention of cardiac arrhythmia by dietary (n-3) polyunsaturated fatty acids and their mechanism of action. J Nutr 1997; 127: 383-393.
31. 2+ handling and cell-to-cell coupling, key factors in prevention of sudden cardiac death. Can J Physiol Pharmacol 2009; 87: 1120-1129.
32. Kostin S, Dammer S, Hein S, Klovekorn WP, Bauer EP, Schaper J. Connexin 43 expression and distribution in compensated and decompensated cardiac hypertrophy in patients with aortic stenosis. Cardiovasc Res 2004; 62: 426-436.
33. Deckelbaum RJ, Worgall TS, Seo T. n-3 fatty acids and gene expression. Am J Clin Nutr 2006; 83: 1520-1525.
34. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection-more than just lipid lowering? Pharmacol Ther 2009; 122: 30-43.
35. Yao J, Hiramatsu N, Zhu Y, et al. Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells. J Am Soc Nephrol 2005; 16: 58-67.
36. Wang LH, Chen JZ, Sun YL, et al. Statins reduce connexin40 and connexin43 expression in atherosclerotic aorta of rabbits. Int J Cardiol 2005; 100: 467-475.
37. Dlugosova K, Okruhlicova L, Mitasikova M, et al. Modulation of connexin-43 by omega-3 fatty acids in the aorta of old spontaneously hypertensive rats. J Physiol Pharmacol 2009; 60: 63-69.